Momenta Pharmaceuticals (MNTA) Tops Q3 EPS by 2c; Revs Light
MNTA Hot Sheet
EPS Growth %: -108.8%Financial Fact:
General and administrative: 10.96M
Today's EPS Names:
TARO, BRLI, TLB, More
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) reports a Q3 loss of $0.38, 2 cents better than estimates. Revenues were $4.0 million vs. $4.74 million consensus.
At September 30, 2009, the Company had cash, cash equivalents, and marketable securities of $107.3 million, compared with $108.5 million at December 31, 2008.
[SM]
At September 30, 2009, the Company had cash, cash equivalents, and marketable securities of $107.3 million, compared with $108.5 million at December 31, 2008.
[SM]
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Talbots, Inc. (TLB) Posts Surprise Q1 Profit; Comps Dip 3.8%
- Patterson Companies, Inc. (PDCO) Tops Q4 EPS by 5c; Guides FY12
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
